|
Malignant Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
As well as identifying genes showing aberrant DNA methylation in certain HN subtypes, we also detected six genes--DBC1, DIO3, FZD9, HS3ST2, MOS, and MYOD1--that were significantly hypermethylated in B-cell, T-cell, and myeloid malignancies.
|
19750229 |
2009 |
|
Malignant Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
Moreover, PUM target mRNAs impinge on human disease genes linked to cancer, neurological disorders and cardiovascular disease.
|
29165587 |
2018 |
|
Malignant Neoplasms
|
0.370 |
CausalMutation
|
group |
CGI |
|
|
|
|
Malignant Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
Our findings suggest that acting, at least in part, through SPIN1 and SPIN3, PUM proteins contribute to a mechanism promoting normal human male germ cell apoptotic status and thus preventing cancer.
|
30197756 |
2018 |
|
Malignant Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
Using four different groups of biopsies obtained from gastric body without history of H. pylori infection (Hp-), gastric body without cancer after H. pylori eradication (cancer-free body), gastric body with early gastric cancer diagnosed after H. pylori eradication (EGC body) and their paired samples from adjacent mucosa of cancer (EGC ADJ), methylation status of five candidate genes (MYOD1, SLC16A12, IGF2, RORA and PRDM5) was examined by the bisulfite pyrosequencing.
|
29978464 |
2019 |
|
Malignant Neoplasms
|
0.370 |
PosttranslationalModification
|
group |
BEFREE |
MYOD1 promoter methylation occurs in various malignancies including colorectal cancer.
|
14767572 |
2004 |
|
Malignant Neoplasms
|
0.370 |
PosttranslationalModification
|
group |
BEFREE |
It is concluded that the detection of increased Myf-3 methylation is a sensitive and specific test of malignancy which may complement other molecular methods that are currently used for the assessment of clonality.
|
11368360 |
2001 |
|
Malignant Neoplasms
|
0.370 |
GeneticVariation
|
group |
BEFREE |
Rhabdomyosarcomas are malignancies associated with a rhabdomyoblastic phenotype which can be demonstrated morphologically or by immunohistochemistry for MYOD1 and myogenin.
|
31696361 |
2020 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
RGD |
Age-associated disruption of molecular clock expression in skeletal muscle of the spontaneously hypertensive rat.
|
22076133 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Detection of the MyoD1 transcript in rhabdomyosarcoma cell lines and tumor samples by reverse transcription polymerase chain reaction.
|
9466584 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetically, a subset of the congenital cases display NCOA2 gene rearrangements, whereas tumors occurring in older children or adults harbor MYOD1 gene mutations with or without coexisting PIK3CA mutations.
|
26501226 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Notably, we found that MyoD1, known as a marker for RMS, was not expressed in the KYM-1 cell line as well as MRT cell lines and fresh tumors.
|
11921280 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas.
|
11272905 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, we report 2 novel fusions (PAX3-WWTR1 and PAX3-NCOA2) in BSNS and show that MyoD1 is more sensitive than myogenin for demonstrating myogenic differentiation in this tumor.
|
30829729 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM.
|
3600778 |
1987 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of the human homolog of MyoD1 therefore can define a tumor as a rhabdomyosarcoma.
|
2601695 |
1989 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Expression of the hypervariable PUM locus in normal and malignant lung: the tumor-associated epitopes are present but masked in normal tissue.
|
2458884 |
1988 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here we report the discovery, through whole-exome sequencing, of a recurrent somatic mutation encoding p.Leu122Arg in the myogenic transcription factor MYOD1 in a distinct subset of ERMS tumors with poor outcomes that also often contain mutations altering PI3K-AKT pathway components.
|
24793135 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The methylation status of 2 age-related loci (ESR1 and MYOD1) and global methylation (the mean of Alu and Sat2) in the normal colonic mucosa of 156 patients with and without colorectal neoplasia were examined.
|
19733896 |
2010 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
MYOD1 promoter methylation was detectable in all samples and was significantly higher in tumor compared to normal mucosa, where the median level of methylation was 5.3 PMR (range 0.03-133.4) in normal mucosa and 42.3 PMR (range 0.44-742.9) in tumor.
|
14767572 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Northern analysis of tumour RNA has been used to examine the expression of members of the myf family of muscle determining genes (myf3, myf4, myf5 and myf6) in a series of 20 rhabdomyosarcomas.
|
1764365 |
1991 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Because the rhabdomyosarcoma locus maps to 11p15.5, MYOD1 is very unlikely to be the primary site of alteration in these tumors.
|
2315312 |
1990 |
|
Carcinoma
|
0.040 |
PosttranslationalModification
|
group |
BEFREE |
Using Southern blot analysis, we examined methylation of Myf-3 in histologically normal colonic mucosae, adenomas and carcinomas from a large series of patients with primary colorectal cancer.
|
10096240 |
1999 |
|
Carcinoma
|
0.040 |
Biomarker
|
group |
BEFREE |
One third of the carcinomas contained hypermethylated Myf-3.
|
8712752 |
1996 |
|
Carcinoma
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Changes in the methylation status of the MyoD1 locus were not seen in any of ten cystadenomas analysed but were present in five of ten LMP tumours and in five of ten carcinomas (P = 0.03).
|
9020485 |
1997 |